Susquehanna International Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-57,192
| Closed | -$212K | – | 10796 |
|
|
2017
Q4 | $212K | Buy |
57,192
+40,080
| +234% | +$164K | ﹤0.01% | 8189 |
|
|
2017
Q3 | $70K | Buy |
+17,112
| New | +$65.5K | ﹤0.01% | 8461 |
|
|
2017
Q2 | – | Sell |
-225,621
| Closed | -$895K | – | 10280 |
|
|
2017
Q1 | $934K | Buy |
225,621
+177,849
| +372% | +$748K | ﹤0.01% | 5266 |
|
|
2016
Q4 | $206K | Buy |
47,772
+5,974
| +14% | +$38.6K | ﹤0.01% | 8615 |
|
|
2016
Q3 | $411K | Buy |
+41,798
| New | +$296K | ﹤0.01% | 6416 |
|
|
2016
Q2 | – | Sell |
-36,946
| Closed | -$251K | – | 9809 |
|
|
2016
Q1 | $282K | Buy |
36,946
+4,350
| +13% | +$33.5K | ﹤0.01% | 7364 |
|
|
2015
Q4 | $434K | Buy |
32,596
+19,623
| +151% | +$338K | ﹤0.01% | 7045 |
|
|
2015
Q3 | $213K | Sell |
12,973
-2,158
| -14% | -$44.2K | ﹤0.01% | 8620 |
|
|
2015
Q2 | $340K | Buy |
+15,131
| New | +$239K | ﹤0.01% | 8323 |
|
|
2015
Q1 | – | Sell |
-3,435
| Closed | -$33.7K | – | 10289 |
|
|
2014
Q4 | $39K | Buy |
+3,435
| New | +$37.3K | ﹤0.01% | 9409 |
|
|
2014
Q3 | – | Sell |
-25,839
| Closed | -$395K | – | 10288 |
|
|
2014
Q2 | $502K | Sell |
25,839
-22,582
| -47% | -$398K | ﹤0.01% | 7474 |
|
|
2014
Q1 | $868K | Buy |
48,421
+32,085
| +196% | +$527K | ﹤0.01% | 5758 |
|
|
2013
Q4 | $173K | Sell |
16,336
-27,403
| -63% | -$306K | ﹤0.01% | 8374 |
|
|
2013
Q3 | $541K | Sell |
43,739
-29,682
| -40% | -$312K | ﹤0.01% | 6308 |
|
|
2013
Q2 | $687K | Buy |
+73,421
| New | +$943K | ﹤0.01% | 5591 |
|
Susquehanna International Group's CASC Position: Q1 2018 in Review
Susquehanna International Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 57,192 shares — an estimated $212K sold.
Susquehanna International Group first reported a position in CASC in Q2 2013 and held it in 15 quarters. The position peaked at $934K in Q1 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Susquehanna International Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Susquehanna International Group sold 57,192 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $212K.
- Susquehanna International Group first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 15 quarters.
- Susquehanna International Group's Cascadian Therapeutics, Inc. position peaked at $934K in Q1 2017.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Susquehanna International Group's 13F filing for Q1 2018, filed 15 May 2018.